REC Share Price

Open 35.40 Change Price %
High 36.39 1 Day -0.02 -0.06
Low 35.23 1 Week -0.59 -1.62
Close 35.83 1 Month 2.64 7.95
Volume 388317 1 Year 10.32 40.45
52 Week High 36.76
52 Week Low 24.24
REC Important Levels
Resistance 2 36.91
Resistance 1 36.46
Pivot 35.82
Support 1 35.20
Support 2 34.75
BIT Italy Most Active Stocks
ISP 2.68 2.29%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.87 -1.14%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
ENEL 4.73 1.07%
SRG 4.13 0.00%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
FTL 3.83 17.13%
XPR 1.56 12.23%
FM 1.77 8.59%
FM 1.77 8.59%
VRW 1.13 6.60%
VRW 1.13 6.60%
More..
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
TFI 0.78 -4.88%
TFI 0.78 -4.88%
TFI 0.78 -4.88%
EDNR 0.73 -2.67%
BMPS 15.87 -2.64%
VIN 1.15 -2.54%
MIC 4.00 -2.44%
MIC 4.00 -2.44%
More..

Recordati (BIT: REC)

REC Technical Analysis 5
As on 22nd May 2017 REC Share Price closed @ 35.83 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 28.55 & Strong Buy for SHORT-TERM with Stoploss of 32.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
REC Target for May
1st Target up-side 35.4
2nd Target up-side 36.37
3rd Target up-side 37.35
1st Target down-side 32.62
2nd Target down-side 31.65
3rd Target down-side 30.67
REC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.recordati.com
REC Address
REC
Via Matteo Civitali 1
Milano, MI 20148
Italy
Phone: 39 02 487871
Fax: 39 02 40 07 37 47
REC Latest News
AstraZeneca, Recordati agree Seloken rights deal   MarketWatch   - 22nd May 17
Recordati S.P.A. (RECI.IT) to Issue $0.37 Dividend   Chaffey Breeze   - 19th May 17
Recordati SPA Declares Dividend of $0.37 (RECI.IT)   Chaffey Breeze   - 09th May 17
Recordati SPA Plans Dividend of $0.37 (RECI.IT)   Markets Daily   - 03rd May 17
Red-Hot Recordati Spawns Four More Drug Billionaires in Italy   Yahoo Finance   - 02nd May 17
RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE ...   GlobeNewswire (press release)   - 11th Apr 17
RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1153.9 MILLION (+10.1 ...   GlobeNewswire (press release)   - 01st Mar 17
RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND ...   GlobeNewswire (press release)   - 09th Feb 17
Italy's Recordati Said to Weigh Options Amid Asian Interest   Bloomberg   - 01st Aug 16
Apricus and Recordati Sign Exclusive License Agreement to Market Topical ...   GlobeNewswire (press release)   - 10th Feb 14
Interactive Technical Analysis Chart Recordati ( REC BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Recordati
REC Business Profile
Recordati S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including antibiotics and antivirals, cardiovascular, central nervous system, dermatological, gastroenterology, genito-urinary system, muscolo-skeletal disorders and pain therapy, and obstetics and gynaecology; and non-prescription pharmaceuticals. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. Its products also include Zanipress/Zanitek, a combination of lercanidipine and enalapril for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Lercanidipine/enalapril fixed combination, which is in pre-registration stage for the treatment of essential hypertension. In addition, it offers gastroenterological drugs, oral rehydration products, probiotics, and OTC brands for gynecological use. Its products under Phase II clinical trials include Cystadrops for the treatment of ocular cystinosis, and REC 0422 to treat overactive bladder and incontinence; and Phase I clinical trials comprise REC 1819 for the treatment of overactive bladder and incontinence, and REC 0438 to treat overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.